COSCIENS Biopharma Inc T.AEZ

Primary Symbol: T.AEZS

Healthcare Biotechnology

COSCIENS Biopharma Inc., formerly Aeterna Zentaris Inc., is a specialty biopharmaceutical company engaged in the development and commercialization of a diverse portfolio of pharmaceutical and diagnostic products, including those focused on areas of unmet medical need. Its lead product, macimorelin (Macrilen; Ghryvelin), is an oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is also engaged in the development of therapeutic assets and proprietary extraction technology, which is applied to the production of active ingredients from renewable plant resources used in cosmeceutical products (i.e., oat beta glucan and avenanthramides, which are found in skincare product brands like Aveeno and Burt’s Bees formulations) and being developed as potential nutraceuticals and/or pharmaceuticals.

TSX:AEZS - Post by User

COSCIENS Biopharma Inc

Bullboard Posts

Comment by rythmanon Aug 23, 2007 12:31pm

124 Views

Post# 13290510

RE: AEZS= $2.82 US or $2.99 Cdn

People are waiting for the complete anlaysis of the data transferred from Solvay. If Solvay's decision to end their license agreement on cetrorelix was mearly based on corporate strategy then the analysis expected by AEZ will clear this up and it is positive then AEZ is truly undervalued and we should see a jump in the price. ON the other hand cetrorelix for the most part has been priced out of the stock and it is possible that we will drift back to around the $2.40 range as we wait fro a positive outcome of the endometriosis analysis.

Bullboard Posts

Debt-free cannabis company set for next stage of growth